Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BERRY GLOBAL GROUP, INC.BERY · Entity 80192 | Director | November 25, 2023 | November 28, 2023 |
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, Chief Financial Officer | May 11, 2026 | May 12, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | Director | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BERRY GLOBAL GROUP, INC.
Report date November 25, 2023 · Filed November 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,728 |
Reported balance
After 2023-11-25 transaction · row 1
1 source rowRow 1 · 2023-11-25 · Exercise / conversion · Acquired 1,970 · Balance 4,728 F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,393 |
Reported balance
After 2023-11-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-25 · Exercise / conversion · Disposed 1,970 · Balance 1,393 F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F2: The award was granted on November 25, 2022 and vested in full on November 25, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
F2: The award was granted on November 25, 2022 and vested in full on November 25, 2023.
Edwards Lifesciences Corp
Report date May 11, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,740 |
Ending reported balance
After 2026-05-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-11 · Exercise / conversion · Acquired 19,830 · Balance 57,744 F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. Row 2 · 2026-05-11 · Tax withholding · Disposed 11,004 · Balance 46,740 |
| Performance RightsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-11 · Exercise / conversion · Disposed 19,830 · Balance 0 F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F2: These Performance Rights expire on May 10, 2030. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 266,318 |
Reported balance
Holding disclosure · report date 2026-05-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 266,318 |
Filing footnotes · ownership attribution and instrument terms
F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4.
F2: These Performance Rights expire on May 10, 2030.
ILLUMINA, INC.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,143 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 113 · Balance 11,143 F1: Mr. Ullem elected to receive 100% of his 2026 board and committee cash retainer fees in Illumina stock. The number of shares issued in lieu of cash is based on the quotient of (i) the cash compensation otherwise payable for the immediately completed quarter divided by (ii) the volume weighted average closing price per share during the immediately completed quarter, calculated by reference to each trading day during such quarter. The amount reported on this Form represents Mr. Ullem's 3rd quarter 2026 retainer fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Ullem elected to receive 100% of his 2026 board and committee cash retainer fees in Illumina stock. The number of shares issued in lieu of cash is based on the quotient of (i) the cash compensation otherwise payable for the immediately completed quarter divided by (ii) the volume weighted average closing price per share during the immediately completed quarter, calculated by reference to each trading day during such quarter. The amount reported on this Form represents Mr. Ullem's 3rd quarter 2026 retainer fees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 03, 2018 Filed Jul 6, 2018 20:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 25,000 | $0.00 Strike: $34.05 | $0.00 |
DisclosureSEC source: 0001225208-18-011520 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,036 Underlying: Common Stock · 25,000 shares Expires 2021-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| July 03, 2018 Filed Jul 6, 2018 20:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 24,200 | $145.65 | $3,524,802.60 |
DisclosureSEC source: 0001225208-18-011520 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,265 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $145.15 to $146.13. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 03, 2018 Filed Jul 6, 2018 20:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 800 | $146.29 | $117,034.40 |
DisclosureSEC source: 0001225208-18-011520 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,465 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $146.16 to $146.49. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 03, 2018 Filed Jul 6, 2018 20:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 25,000 | $34.05 | $851,250.00 |
DisclosureSEC source: 0001225208-18-011520 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 00:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 25,000 | $0.00 Strike: $34.05 | $0.00 |
DisclosureSEC source: 0001225208-18-010292 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,036 Underlying: Common Stock · 25,000 shares Expires 2021-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 00:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 16,510 | $140.79 | $2,324,398.32 |
DisclosureSEC source: 0001225208-18-010292 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,265 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $140.40 to $141.38. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 00:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,490 | $141.62 | $1,202,362.29 |
DisclosureSEC source: 0001225208-18-010292 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,775 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $141.43 to $141.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 00:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 25,000 | $34.05 | $851,250.00 |
DisclosureSEC source: 0001225208-18-010292 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 3,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009678 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,275 Underlying: Common Stock · 3,275 shares Expires 2025-05-16 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 22,500 | $0.00 Strike: $135.83 | $0.00 |
DisclosureSEC source: 0001225208-18-009678 · doc4.xml · derivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2025-05-16 F2 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009678 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,265 F1 · shares: These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 16, 2018 Filed May 19, 2018 00:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 9,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009581 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,712 shares Expires 2018-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · price: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · derivative.exercise_date: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · derivative.underlying_shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document |
| May 16, 2018 Filed May 19, 2018 00:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 4,816 | $136.43 | $657,046.88 |
DisclosureSEC source: 0001225208-18-009581 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,640 F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document |
| May 16, 2018 Filed May 19, 2018 00:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 9,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009581 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · price: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document |
| May 14, 2018 Filed May 17, 2018 00:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 1,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009496 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 62,780 Read SEC document |
| May 14, 2018 Filed May 17, 2018 00:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 1,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009496 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,744 Read SEC document |
| May 14, 2018 Filed May 17, 2018 00:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,103 | $138.11 | $152,335.33 |
DisclosureSEC source: 0001225208-18-009496 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,865 Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 25,000 | $0.00 Strike: $34.05 | $0.00 |
DisclosureSEC source: 0001225208-18-009209 · doc4.xml · derivative · entry 6 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,036 Underlying: Common Stock · 25,000 shares Expires 2021-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 14,253 | $135.16 | $1,926,409.82 |
DisclosureSEC source: 0001225208-18-009209 · doc4.xml · nonDerivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,968 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F4 · price: This transaction was executed in multiple trades at prices ranging from $134.49 to $135.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,847 | $133.86 | $1,184,220.49 |
DisclosureSEC source: 0001225208-18-009209 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,221 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $133.43 to $134.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,900 | $135.59 | $257,613.02 |
DisclosureSEC source: 0001225208-18-009209 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,068 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $135.49 to $135.66. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 25,000 | $34.05 | $851,250.00 |
DisclosureSEC source: 0001225208-18-009209 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 01:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 25,000 | $0.00 Strike: $34.05 | $0.00 |
DisclosureSEC source: 0001225208-18-007486 · doc4.xml · derivative · entry 8 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,036 Underlying: Common Stock · 25,000 shares Expires 2021-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 01:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,544 | $138.47 | $906,131.97 |
DisclosureSEC source: 0001225208-18-007486 · doc4.xml · nonDerivative · entry 6 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,968 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F6 · price: This transaction was executed in multiple trades at prices ranging from $137.86 to $138.85. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 01:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,546 | $135.43 | $751,106.98 |
DisclosureSEC source: 0001225208-18-007486 · doc4.xml · nonDerivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,512 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F5 · price: This transaction was executed in multiple trades at prices ranging from $134.78 to $135.77. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 01:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,300 | $137.30 | $727,706.96 |
DisclosureSEC source: 0001225208-18-007486 · doc4.xml · nonDerivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,058 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F4 · price: This transaction was executed in multiple trades at prices ranging from $136.86 to $137.68. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 01:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,690 | $136.12 | $638,384.51 |
DisclosureSEC source: 0001225208-18-007486 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,358 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $135.78 to 136.67. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 01:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,920 | $139.00 | $405,868.61 |
DisclosureSEC source: 0001225208-18-007486 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,048 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $138.86 to $139.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 01:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 25,000 | $34.05 | $851,250.00 |
DisclosureSEC source: 0001225208-18-007486 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 20:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 25,000 | $0.00 Strike: $34.05 | $0.00 |
DisclosureSEC source: 0001225208-18-006837 · doc4.xml · derivative · entry 6 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,036 Underlying: Common Stock · 25,000 shares Expires 2021-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 20:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 16,730 | $137.06 | $2,292,997.07 |
DisclosureSEC source: 0001225208-18-006837 · doc4.xml · nonDerivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,968 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F4 · price: This transaction was executed in multiple trades at prices ranging from $136.48 to $137.46. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 20:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,170 | $137.73 | $987,506.89 |
DisclosureSEC source: 0001225208-18-006837 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,698 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $137.48 to $138.42. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 20:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,100 | $138.75 | $152,622.03 |
DisclosureSEC source: 0001225208-18-006837 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,868 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $138.59 to $139.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 20:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 25,000 | $34.05 | $851,250.00 |
DisclosureSEC source: 0001225208-18-006837 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 23:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 14,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003868 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 61,659 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 23:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 14,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003868 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,968 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 23:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 11,643 | $133.82 | $1,558,066.26 |
DisclosureSEC source: 0001225208-18-003868 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,023 Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 22:19 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | GrantDirector Stock Option (Right To Buy) · Derivative | 6,500 | $0.00 Strike: $54.33 | $0.00 |
DisclosureSEC source: 0001140361-18-007282 · doc1.xml · derivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 6,500 shares Expires 2028-02-08 F1 · derivative.exercise_date: Granted under the 2015 Long-Term Incentive Plan. Option fully vested. Read SEC document |
| July 10, 2017 Filed Jul 11, 2017 22:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 297 | $118.17 | $35,096.49 |
DisclosureSEC source: 0001225208-17-012564 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,666 F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person; and it reflects 271 shares that were previously reported as directly held but are currently held in trust. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 3,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009774 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,775 Underlying: Common Stock · 3,775 shares Expires not disclosed F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · derivative.underlying: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 26,600 | $0.00 Strike: $110.25 | $0.00 |
DisclosureSEC source: 0001225208-17-009774 · doc4.xml · derivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,600 Underlying: Common Stock · 26,600 shares Expires 2024-05-10 F3 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 3,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009774 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,234 F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009633 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2017-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.exercise_date: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.underlying_shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 5,479 | $110.58 | $605,867.82 |
DisclosureSEC source: 0001225208-17-009633 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,230 F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009633 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 11,815 | $89.74 | $1,060,278.10 |
DisclosureSEC source: 0001225208-17-004571 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,209 F1 · kind: Issuer's withholding of shares of common stock issuable upon vesting of restricted stock units to satisfy the Reporting Person's related tax withholding obligation. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person; and it reflects 42,312 shares that were previously reported as directly held. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 21:04 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $49.53 | $0.00 |
DisclosureSEC source: 0001140361-17-005397 · doc1.xml · derivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 7,500 shares Expires 2027-02-06 F1 · derivative.exercise_date: Granted under the 2015 Long-term Incentive Plan. Options fully vested. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 19:51 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | GrantDirector Stock Options (right to buy) · Derivative | 9,000 | $0.00 Strike: $45.62 | $0.00 |
DisclosureSEC source: 0001140361-16-079208 · doc1.xml · derivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2026-09-05 F1 · derivative.exercise_date: Granted under the 2015 Long-Term Incentive Plan. Options fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.